No Data
No Data
Theriva Biologics Announces Presentation Of Data From The Phase 1b/2a Clinical Trial OOf SYN-004 In Allogeneic Hematopoietic Cell Transplant Recipients
Express News | Theriva Biologics Announces Presentation of Data From the Phase 1B/2a Clinical Trial of Syn-004 (Ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
Theriva Biologics Says IDMC Considers VCN-01 to Be Well Tolerated
Theriva Biologics Announces Positive Outcomes From the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company's Phase 2b Clinical Trial of VCN-01 in Combination With Chemotherapy for Metastatic Pancreatic Ductal...
Theriva Biologics to Present at the 2025 NeauxCancer Conference
Maxim Group Maintains Theriva Biologics(TOVX.US) With Buy Rating, Maintains Target Price $6